Atavistik Bio

Harnessing the power of allostery to develop transformative medicines

Atavistik Bio was founded in 2021, is headquartered in Cambridge, United States, lists 11–50 employees, and has $225.3M in recorded funding across 4 rounds.

Employees
11–50
Founded
2021
Business Model
B2B
Total Funding
$225.3M
Last Round
$40.0M Extension RoundMar 2026
Rounds
4

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 4 funding rounds and 9 investors for this company. The full record is or through the API.

About

Atavistik Bio is a clinical-stage biotechnology company developing novel allosteric small molecule therapeutics for rare hematological disorders and cancers. Its lead asset ATV-1601 is an oral allosteric AKT1-selective inhibitor targeting Hereditary Hemorrhagic Telangiectasia, which received FDA IND clearance and Fast Track designation in 2026. The company also advances a JAK2 V617F mutant-selective inhibitor for myeloproliferative neoplasms.

Summary

Atavistik Bio is a Biotech company based in Cambridge, United States, founded in 2021. It lists 11–50 employees. It has raised $225.3M in total across 4 rounds, most recently a $40.0M Extension Round in Mar 2026. Investors include Lux Capital, Nextech Invest and The Column Group.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Extension RoundExtension RoundMar 2026
$40.0M

Sign up to see all 4 events

Funding: Series A through Extension Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Atavistik Bio on Indexed.vc
<a href="https://indexed.vc/companies/atavistik-bio"><img src="https://indexed.vc/api/badge/company/atavistik-bio" alt="Atavistik Bio on Indexed.vc" width="260" height="76" /></a>